For Immediate Release
Chicago, IL – May 19, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Boeing (NYSE: (BA - Free Report) – Free Report ), AbbVie (NYSE: (ABBV - Free Report) – Free Report ), UnitedHealth (NYSE: (UNH - Free Report) – Free Report ), Consolidated Edison (NYSE: (ED - Free Report) – Free Report ) and Cisco (NASDAQ: (CSCO - Free Report) – Free Report ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Thursday’s Analyst Blog:
New Stock Research Reports for Today: BA, ABBV, UNH & More
Today's Research Daily features new research reports on 16 major stocks, including Boeing (NYSE: (BA - Free Report) – Free Report ), AbbVie (NYSE:(ABBV - Free Report) – Free Report ) and UnitedHealth (NYSE: (UNH - Free Report) – Free Report ). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today’s research reports here >>>
Boeing shares have surged +39.6% over the past one-year, outperforming the Zacks Aerospace & Defense sector, which gained +20.9% during the same time period. The Zacks analyst stresses that rising demand for its commercial airplanes on the back of steady improvement in passenger and freight traffic is the major factor behind the surge in Boeing shares. These developments reflect the company’s latest expansion on the international front, apart from its strong presence in the domestic aviation market. The improving outlook for defense spending under the Trump administration is another long-term positive in the Boeing story. However, challenges including uncertain fate of high-cost programs, risks related to key project executions, order cancellations as well as stiff competition might have a negative impact on the company. (You can read the full research report on Boeing here >>> )
AbbVie shares have gained +10.2% over the last one year, outperforming the large cap pharma industry, which has gained +4.4% over the same period. The stock as well as the industry has lagged the broader market, however, on continued macro uncertainty related to drug pricing. AbbVie reported better-than-expected results in the first quarter, surpassing expectations for both earnings and sales. The Zacks analyst likes its key drug Humira’s performance. Sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. On the flip side, the Zacks analyst points out that Viekira faces intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to the market. (You can read the full research report on AbbVie here >>> )
UnitedHealth shares have lagged the peer group lately, with the stock up +5.5% in the year-to-date period vs. the Zacks HMO industry’s +10.5% gain. A big reason for the stock’s recent underperformance are questions about the company’s Medicare Advantage policies in recent years following a whistleblower accusations. The company’s decision to reduce its exposure to the troubled public exchange business is a likely another issue. Though this move will shield it from losses in this business, the company’s premium revenues will be affected. These challenges notwithstanding, the Zacks analyst likes the company’s strong fundamentals and diversified operations which should help it counter these headwinds. The company raised its 2017 guidance on the back of its solid first-quarter earnings. UnitedHealth has also witnessed an upward revision in earnings estimates for 2017 over the last 30 days. (You can read the full research report on UnitedHealth here >>> )
Other noteworthy reports we are featuring today include Consolidated Edison (NYSE:(ED - Free Report) – Free Report ) and Cisco (NASDAQ: (CSCO - Free Report) – Free Report ).
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >> .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.
Get the full Report on BA - FREE
Get the full Report on ABBV - FREE
Get the full Report on UNH - FREE
Get the full Report on ED - FREE
Get the full Report on CSCO - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.